Botulinum toxin (Botox) for hair loss

Key takeaways

• Not approved for hair. In the US, Botox is labelled for conditions such as overactive bladder, chronic migraine, spasticity and severe underarm sweating, and hair loss is not an indication, so use for hair is off-label. EU and UK licensing was not checked.
• The label carries a boxed warning that toxin effects can spread from the injection site, with swallowing and breathing difficulties that can be life-threatening. No severe events were reported in the scalp-hair trials, but they are small.
• Pooled data lean positive but rest on weak studies. A meta-analysis of 8 studies found an effect size of 1.02 on hair count versus controls (Cheng 2025). A review of 40 articles (689 patients, 25 to 200 units) found most studies in male pattern loss reported mild or non-significant growth and could not justify it over established treatments (Perez 2025).
• The newest blinded trial was negative. In 15 men given 100 units once, hair density did not rise at 6 months and frontal hair thickness fell in both groups (Lima-Galindo 2025).
• Where it was positive it was an add-on. In 60 men, 60 to 70 units over 30 to 35 sites plus 5% minoxidil gave better growth and quality-of-life scores than minoxidil alone at 4 and 6 months (Yu 2024).
• Injection site is unsettled. In a 29-patient split-scalp trial, injections into the muscles around the scalp raised density more than injections into the bald skin, and hurt less (Li 2024).
• For women there is very little. In 10 women with female pattern loss, three had mild improvement, six no change and one got worse at 3 months (Hu 2024).
• It has a clearer role for scalp pain. In 21 patients with trichodynia, 90.5% reported improvement, but the study was retrospective and uncontrolled (Saceda-Corralo 2026).

How it might work

The idea is that tension and reduced blood flow in the scalp muscles contribute to pattern hair loss, and relaxing them improves oxygenation. Other proposals involve less nerve-driven inflammation. None is proven in a human balding scalp.

What the studies show

• Zhou 2020, 63 people: 100 units at 30 sites every 3 months, with or without finasteride; counts rose in both groups, and the combination did better (effective rates 73.3% vs 84.8%) (Zhou 2020).
• Li 2024: muscle injections beat intradermal injections for density (p under 0.001); both raised hair diameter (Li 2024).
• A 2022 review of five uncontrolled studies in 165 men reported response rates of 75 to 79%, with no control groups and low quality (English 2022).
• A 2024 network meta-analysis found oral 5-alpha-reductase inhibitors more effective than newer options such as botulinum toxin, microneedling and photobiomodulation in men (Gupta 2024).

How to read this: doses ranged from 25 to 200 units, brands use different unit scales, and protocols differ in site count, depth and repeats. The meta-analysis included few blinded randomized studies and predates the 2025 negative trial.

How it's used in studies

Trials used 20 to 35 injection sites with 2 to 5 units per site into the skin, repeated every 3 to 4 months in some trials and given once in others. It requires a licensed prescriber; avoid unregulated or counterfeit toxin.

Side effects and safety

• Boxed warning for distant spread of toxin effect. Seek urgent care for difficulty swallowing or breathing, widespread weakness, or drooping eyelids or brows.
• Injections near the forehead can affect brow position.
• Not studied in pregnancy or breastfeeding for hair.
• Cost is high, since each session needs 50 to 200 units and repeats are needed.

Bottom line

Botulinum toxin for hair is experimental. It might be a small add-on to minoxidil in men, but the most careful recent trial found nothing, and it does not replace finasteride or minoxidil. See the treatment ladder. Discuss with a doctor.